|
March,
2011: Dr. Thomas Dooley joined Agenta as VP for R&D.
December,
2010: Dr. Chuanyu Li joined Agenta as a full-time research
associate (see Personnel).
October, 2010: Agenta's technology was presented by Dr. DeCarlo at the
American Society for Matrix Biology meeting in Charleston, SC.
August, 2010: Agenta's core technology was published in the
open-access, peer-reviewed journal BMC Biotechnology (BioMed Central).
January, 2010: Agenta Biotechnologies, Inc. held its annual joing
shareholder and board meeting in Weston, Florida.
May
6th, 2009: Bonenta, Inc., a subsidiary of Agenta Biotechnologies,
Inc., has been accepted to present in the Business Forum at the 2009
International BIO conference in Atlanta, GA.
September 7th, 2008: Bonenta, Inc., a subsidiary of Agenta
Biotechnologies, Inc., has been accepted into the NIH 2008-2009 SBIR
Commercialization Assistance Program (NIH-CAP). The CAP, now in
its fifth year, is designed to help some of the nation’s most promising
life science small companies develop their commercial businesses and
transition their SBIR-developed products into the marketplace.
Dr. DeCarlo, CEO of Bonenta, Inc., is representing Bonenta, Inc. in
this prestigious program.
September 1, 2008: Agenta Biotechnologies, Inc., a platform
technology company addressing unmet needs in wound healing and tissue
regeneration, formed a subsidiary focused on bone healing, named
Bonenta, Inc. Bonenta’s lead product candidate is a co-activator
for bone growth factors enabling rapid and effective bone regeneration
with a significantly improved safety profile addressing current market
needs.
August 4, 2008: Agenta has begun a partnership with Biological
Innovations, LLC and Dr. Don Petersen who will provide expertise in
material science and other biological assays.
August 1, 2008: The National Institutes
of Health has awarded Agenta Biotechnologies the second year of a phase
2 SBIR grant providing a half million dollars for the advancement of
Agenta's lead product candidate
for bone regeneration.
July 3, 2008: Dr. April Ellis presented data to the
International Association of Dental Research delegates. Dr. Ellis
has found that a prototype biologic of Agenta Biotechnologies, when
applied to a healing wound in a chitosan bandage, significantly
promotes the healing response.
April 5, 2008: Agenta Biotechnologies today announced the
presentation of preclinical data from its bone healing program at the
37th Annual Meeting of the American Academy of Dental Research.
The Company is developing Perl.D1, a therapeutic proteoglycan DNA
product that will be delivered in orthopedic, spine, and craniofacial
bone surgery for bone regeneration. Results demonstrated that
Perl.D1 generates heparan sulfate carbohydrate polymers which bind to
fibroblast growth factors (FGFs), important in the healing
process. Furthermore, in vivo delivery of Perl.D1 via a common
bone graft material resulted in significantly better bone healing – a
more dense bone with histological evidence of rapid bone regeneration
stimulated by the augmented graft material – in an experimental
model. “We know that heparan sulfate and growth factors play a
vital role in the healing process, so we are very pleased that Perl.D1
has demonstrated effectiveness in bone repair,” stated Dr. Arthur
DeCarlo, Agenta’s President and Chief Scientific Officer.
“Perl.D1 is part of a new class of compounds that can generate a
customized heparan sulfate in the healing bone. This personalized
approach has the potential to vastly improve how well, and how fast,
broken bones, bone grafts, fusions, or implants heal.”
October 20, 2007: Agenta Biotechnologies held its Annual Meeting at the
Innovation Depot in Birmingham, Alabma. Click here to view the President's Letter.
September
20, 2007: Dr. Arthur DeCarlo was nominated and accepted into the
Birmingham Venture Club Accelerator Program. The mission of this
program is "To equip the most promising entrepreneurs in the Birmingham
area with the knowledge, access to resources and ongoing mentoring
relationships that are essential to establishing and rapidly growing
successful businesses.” The 2007 Entrepreneurs Accelerator
Program kicked off at the Member Luncheon of the Club on Thursday,
September 20.
September 4th, 2007: Agenta Biotechnologies successfully
recruited and hired Dr. Wengsheng Pan as Director of Molecular Biology.
August 2nd, 2007: The National Institutes
of Health has awarded Agenta Biotechnologies two research grant awards
- a
phase 1 and a phase 2 SBIR - totaling $515,318. The grants
provide R&D funding to advance Agenta's Perl.D1 product candidate
for bone regeneration, and for product development in skin and gingival
wound
healing.
June 18th, 2007: Agenta
Biotechnologies presents at
BIO VentureForum East 2007, in Montreal, Quebec. The
Biotechnology Industry Organization (BIO), in
partnership with 14 state biotechnology associations and BIOTECanada
brought venture capitalists together with promising seed, early- and
late-stage private biotechnology product and platform companies from
the East Coast.
May 17th, 2007: Dr. Kathy Nugent has accepted the position of CEO
for Agenta Biotechnologies, Inc. Dr. Nugent brings experience
with investor relations as Senior Vice President of Corporate
Communications at Burns McClellan Life Sciences Communications
firm. Dr. Nugent spent several years involved with cancer-related
pharmaceutical clinical trials and as leader of two neuroscience
projects in the Department of Pharmacology at Cornell University
Medical College prior to joining Burns McClellan.
May 1, 2007: Agenta Biotechnologies moves its operations to the
newly constructed Innovation Depot, a business and biotechnology
incubator in downtown Birmingham, Alabama. The move provides
Agenta with expanded office and laboratory space.
April 28th, 2007: Agenta submits a continuation-in-part to extend
the scope and territory of its patent technology platform.
April 10th, 2007: Dr. DeCarlo,
President and Science Director of Agenta Biotechnologies, Inc., met
with investors and industry representa at the 2007 BioWindhover meeting
in our nation's capitol regarding Agenta's Therapeutic Proteoglycan DNA
Delivery platform and early-stage pipeline therapeutics for treatment
Alzheimer's disease and for the treatment of damaged skin, including
wrinkles.
March 6th, 2007: The Birmingham Business
Journal lists Agenta
Biotechnologies as a "2006 highlight" of Birmingham's business
incubator clients, referring to the awarding of the U.S. patent to
Agenta. The business incubators referred to are the
Entrepreneurial Center, and the Office for the Advancement of
Developing Industries (OADI). These business incubators will be
combined as the Innovation Depot in Birmingham, Alabama during the
Spring of 2007.
November 28th, 2006: US Patent
#7,141,551 is issued, assigned wholly to
Agenta Biotechnologies, Inc. The patent, entitled "Wound and
Cutaneous Injury Healing with a Nucleic Acid Encoding Perlecan" is
Agenta's first patent and provides a broad technology platform for a
range of orthopedic and tissue regenerative uses. What makes
Agenta’s technology a scientific and engineering innovation is that the
patented novelty lies in delivering DNA, i.e., nucleic acids, not
protein to generate natural perlecan expression. DNA delivery is
significantly more cost effective and allows for important variations
to be incorporated into the expressed product according to local
needs. Under current practice, proteins are approved for bone
regenerative procedures, but their success is limited. Moreover,
molecular perlecan can increase vascularity and improve the wound
environment, possibly combined with other adjuncts. This
technology is proposed to overcome the shortcomings in current
regenerative treatment by its ability to increase vascularity and
improve the wound environment as a stand-alone technology or perhaps
combined with other biological adjuncts.
|
